New First-Line Treatment Approval for Triple-Negative Breast Cancer – Dana-Farber Cancer Institute

Dana-Farber Cancer Institute shared a post on LinkedIn:

“Yesterday, the FDA approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer. This action is based on results from the ASCENT–03 and -04 global clinical trials, which Sara Tolaney, MD, MPH, chief of the Division of Breast Oncology, helped to lead.

‘As oncologists and investigators, we’re always trying to move more effective therapies into earlier lines of treatment because we want patients to be able to have robust responses that potentially will translate into survival outcomes,’ says Tolaney.

‘This approval is heartening news for patients and the clinical community, and I believe offers a practice-changing first-line treatment option for all patients across PD-L1 status.'”

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

Other articles about Dana-Farber Cancer Institute on OncoDaily.